oral semaglutide cardiovascular outcomes soul trial results 2024 2025 nejm soul trial oral semaglutide cardiovascular outcomes 2024 2025 Updates in Medicine SELECT Trial

Then theres the disappointment and frustration when nothing seems to work

The FDA has approved Rybelsus (semaglutide) the first-ever oral diabetes medication proven to protect against heart attacks and strokes, in addition to controlling blood sugar

Because GLP-1 drugs suppress appetite so strongly, many users unintentionally fail to meet basic protein requirements

CJC-1295 + Ipamorelin and Sermorelin are the most frequently prescribed options here, because both restore the growth hormone pulses that decline in tandem with estrogen, partially offsetting the compounding hormonal shift that drives vasomotor symptoms